David C. Hastings

Board Director

Director

Entasis Therapeutics Holdings Inc.Scynexis Inc Arbutus Biopharma Corp

Insider activity · 24 months0 buys1 saleCumulative net flow

Nov 24 · 0 buys · 0 salesDec 24 · 0 buys · 0 salesJan 25 · 0 buys · 0 salesFeb 25 · 0 buys · 1 saleMar 25 · 0 buys · 0 salesApr 25 · 0 buys · 0 salesMay 25 · 0 buys · 0 salesJun 25 · 0 buys · 0 salesJul 25 · 0 buys · 0 salesAug 25 · 0 buys · 0 salesSept 25 · 0 buys · 0 salesOct 25 · 0 buys · 0 salesNov 25 · 0 buys · 0 salesDec 25 · 0 buys · 0 salesJan 26 · 0 buys · 0 salesFeb 26 · 0 buys · 0 salesMar 26 · 0 buys · 0 salesApr 26 · 0 buys · 0 salesMay 26 · 0 buys · 0 salesJun 26 · 0 buys · 0 salesJul 26 · 0 buys · 0 salesAug 26 · 0 buys · 0 salesSept 26 · 0 buys · 0 salesOct 26 · 0 buys · 0 sales

Total declarations

Companies

▲ Purchases (0 ops.)

—

▼ Sales (1 ops.)

€71k

Latest filing published 30 Jun 2026 for SCYNEXIS INC. Read the official filing

Filing timeline

BuySale

David C. Hastings

Insider track record

Disclosed buys

Disclosed sells

Not enough buy signals with a settled T+90 horizon to measure a track record yet.

Signal history

David C. Hastings: trading record in brief

David C. Hastings, listed as board member, has filed trades across 3 companies (mainly through SEC (Form 4)), most often in Scynexis Inc, Arbutus Biopharma Corp and Entasis Therapeutics Holdings Inc. Over a trading history stretching from 18 January 2022 to 26 June 2026, the count stands at 11 filings.

No open-market purchase appears, only 1 sale worth €71k. Besides market trades, the filings include 9 share grants.

The record was last updated on 30 June 2026 with a share grant in Scynexis Inc. Typically, a trade is published a median of 4 days after it takes place. US insiders must file a Form 4 within two business days of a trade. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.